Investor Relations - RNS Announcements

RNS Announcements

 

To sign up to receive Investor News as it is released please email Walbrook PR

31/03/21 Exercise of Options and Total Voting Rights
26/03/21 Exercise of Options and Total Voting Rights
22/03/21 CE-Mark of Mologic COVID-19 lateral flow antigen test
19/03/21 Exercise of Options and Total Voting Rights
15/03/21 Statement re. Government press release
15/03/21 UK Public Sector Contract disclosure
08/03/21 Grant of Options
02/03/21 Contract with Screen4 for COVID-19 antibody laboratory-based testing service
24/02/21 UK-RTC statement on AbC-19TM rapid antibody test
19/02/21 Director/PDMR Shareholding, Exercise of Options and Total Voting Rights
18/02/21 Director/PDMR Shareholding, Exercise of Options and Total Voting Rights
16/02/21 AbC-19TM rapid antibody test performance data
15/02/21 Director/PDMR Shareholding, Exercise of Options and Total Voting Rights
11/02/21 UK Government manufacturing contract. Board appointment & trading update
11/02/21 Directorate Change
08/02/20 Statement re. media comment
02/02/21 Exercise of Options and Total Voting Rights
28/01/21 Exercise of Options and Total Voting Rights
26/01/21 Update re AbC-19TM Rapid Test & Launch of COVID-19 antibody laboratory-based testing service
26/01/21 Launch of COVID-19 antibody laboratory-based testing service
22/01/21 Exercise of Options and Total Voting Rights
11/01/21 Exercise of Options and Total Voting Rights
29/12/20 Update re AbC-19TM Rapid Test
24/12/20 Mologic CE Mark Rapid Antigen Test
11/12/20 Exercise of Options and Total Voting Rights
07/12/20 Exercise of Options and Total Voting Rights
02/10/20 Director/PDMR Shareholding
30/11/20 Exercise of Options and Total Voting Rights
30/11/20 Interim Results - Six months ended 30 September 2020
23/11/20 Exercise of Options and Total Voting Rights
17/11/20 UK-RTC Update
16/11/20 Holding(s) in Company
16/11/20 Holding(s) in Company
13/11/20 Exercise of Options and Total Voting Rights
12/11/20 UK-RTC Statement
12/11/20 Response to media comment
11/11/20 Investor presentation – Q&A Update
09/11/20 Exercise of Options and Total Voting Rights
06/11/20 Exercise of Options and Total Voting Rights
03/11/20 Chinese approval for self-test use of Food Detective® test
30/10/20 Exercise of Options and Total Voting Rights
29/10/20 Notification of Major Holdings
28/10/20 Trading update and notice of interim results
20/10/20 Notice of Trading Update and Investor Presentation
20/10/20 Exercise of Options and Total Voting Rights
19/10/20 UK-RTC contract for the Supply of Goods
14/10/20 Exercise of Options and Total Voting Rights
09/10/20 Exercise of Options and Total Voting Rights
06/10/20 Notification of Major Holdings
06/10/20 UK Government contract for UK-Rapid Test Consortium
02/10/20 Preliminary report published by Ulster University 
15/09/20 TR-1: Standard form for notification of major holdings
14/09/20 Exercise of Options and Total Voting Rights
07/09/20 Statement regarding Share Price Movement
07/09/20 Completion of self-test usability study for AbC-19™ Rapid test
03/09/20 CE-Mark for Mologic COVID-19 antibody test
01/09/20 Exercise of Options and Total Voting Rights
26/08/20 Result of Annual General Meeting
26/08/20 Exercise of Options and Total Voting Rights
24/08/20 Exercise of Options and Total Voting Rights
21/08/20 WHO Prequalification Received
30/07/20 Update on progress of UK-Rapid Test Consortium
24/07/20 Exercise of Options and Total Voting Rights
23/07/20 Notice of AGM and posting of Annual Report
20/07/20 Investor Presentation
14/07/20 Final Results - Year Ended 31 March 2020
10/07/20 Result of General Meeting
10/07/20 Notice of Results
08/07/20 Result of Open Offer
02/07/20 COVID-19 ELISA - Approval for sale in India
29/06/20 Update on progress of UK-Rapid Test Consortium - Design Freeze
22/06/20 Publication of Shareholder Circular
22/06/20 Investor presentation
19/06/20 Fundraising to raise gross proceeds of up to £11m
09/06/20 Trading Update
03/06/20 Update on progress of UK-Rapid Test Consortium
01/06/20 Holdings in Company
27/05/20 Statement regarding share price movement
22/05/20 Exercise of Options and Total Voting Rights
07/05/20 Exercise of Options and Total Voting Rights
04/05/20 Exercise of Options and Total Voting Rights
30/04/20 Exercise of Options and Total Voting Rights
29/04/20 Holdings in Company
28/04/20 Holdings in Company
28/04/20 Supply Agreement with Clinton Health Access Initiative, Inc.
27/04/20 CE-Mark of COVID-19 ELISA antibody test
20/04/20 Material Transfer Agreement with Mologic on COVID-19 
20/04/20 Holdings in Company
16/04/20 Holdings in Company
16/04/20 Holdings in Company
14/04/20 Holdings in Company
09/04/20 MOU on COVID-19 Consortium
06/04/20 MSF Trial Publication
06/04/20 Holding(s) in Company
02/04/20 ODX Trading Update
02/04/20 Chinese Approval for Food Detective Test
24/01/20 Grant of Options
17/01/19 VISITECT CD4 350 Nigeria MOH approval
02/12/19 Interim Results - Year Ended 30 September 2019
02/12/19 Nigerian order for VISITECT CD4
25/11/19 Update on Allergy Test Menu
21/11/19 Investor Briefing
22/10/19 Result of AGM
22/10/19 Trading Update and Notice of Interim Results
15/10/19 Holding(s) in Company
14/10/19 Holding(s) in Company
14/10/19 Holding(s) in Company
11/10/19 Holding(s) in Company
10/10/19 Result of General Meeting
27/09/19 Notice of AGM and posting of annual report
23/09/19 Placing & Subscription and Notice of General Meeting
23/09/19 Final Results – Year Ended 31 March 2019
16/09/19 Update on VISITECT® CD4 Advanced Disease test
10/09/19 Purchase Order for Chinese Food Detective® test
20/08/19 VISITECT CD4 Advanced Disease order
16/08/19 Results, Trading Update & Nigerian CD4 Order
06/06/19 Announcement of Results
05/06/19 Holding(s) in Company
03/06/19 Holding(s) in Company
22/05/19 Subscription to raise c.£635,000
17/04/19 Trading Update
18/03/19 CD4 Advanced Disease CE-Mark
06/03/19 VISITECT CD4 Update
01/03/19 Board Appointment
29/01/19 VISITECT CD4 Advanced Disease Validation
10/12/18 Directorate Change
03/12/18 Interim Results - Six months ended 30 Sep 2018
19/10/18 Holding(s) in Company
10/10/18 Trading Update
27/09/18 Allersys CE Mark
14/09/18 Result of AGM
10/09/18 Holding(s) in Company
06/06/18 FINAL RESULTS FOR THE YEAR ENDED 31 MARCH 2018
06/08/18 VISITECT® CD4 Advanced Disease Development Update
18/07/18 VISITECT® CD4 commercialisation update
02/07/18 Notice of Results - RNS
28/06/18 Disposal of Infectious Disease Business
21/05/18 VISITECT CD4 Update
08/05/18 Allersys CE Mark
02/05/18 Closure of Omega Diagnostics GmbH
24/04/18 PDRM Dealing
24/04/18 Holding(s) in Company
23/04/18 Holding(s) in Company
23/04/18 Director/PDMR Shareholding
23/04/18 Holding(s) in Company
23/04/18 Director/PDMR Shareholding
20/04/18 Allersys Distributon Agreement
10/04/18 Strategic Review of Operations and Trading Update
10/04/18 Price Monitoring Extension
12/01/18 Holding(s) in Company
21/12/17 Allersys® CE-Mark
14/12/17 CEO Succession 
29/11/17 VISITECT® CD4 CE-Mark
01/11/17 Change of Registered Address
23/10/17 Trading Update and Notice of Interim Results
16/10/17 US Supply Agreement
10/10/17 Holding(s) in Company
05/09/17 Exercise of Options and Total Voting Rights
29/08/17 Result of AGM
18/07/17 Result of General Meeting
17/07/17 Result of Open Offer
06/07/17 Sale and leaseback of the building owned by Omega GmbH
30/06/17 Result of Proposed Fundraising
30/06/17 Proposed Fundraising
30/06/17 Final Results - FY17 
25/04/17 Trading Update and Notice of Results
21/04/17 Holding(s) in Company
29/03/17 VISITECT® Malaria CE-Mark and successful Indian FDA inspection
07/03/17 Holding(s) in Company
27/02/17 Holding(s) in Company
22/01/17 Update on discussions with Immunodiagnostic Systems Holdings plc
11/01/17 ISO accreditation for manufacturing facility in Pune, India
24/11/16 Holding(s) in Company
17/10/16 Trading Update and Notice of Interim Results
10/08/16 Result of AGM
02/08/16 R&D Grant Funding
04/07/16 Holding(s) in Company
01/07/16 Holding(s) in Company
27/06/16 Final Results - FY16
09/06/16 Holding(s) in Company
21/04/16 Trading Update and Notice of Results
08/02/16 Holding(s) in Company
   

Company Information

Copyright 2021 Omega Diagnostics Group PLC | Privacy